Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -476.77% is 87% below its 5-year average of -254.34%, around the middle of its 5-year range (-800.68%–-27.58%).
As of the fiscal period ended Tuesday, June 30, 2026.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -476.77%.
RETURN ON EQUITY (ROE)
-476.77%
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
-422.57%
RETURN ON EQUITY (ROE) AVG 5Y
-254.34%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
-12.83%
CURRENT VS 5Y AVG
-87.45%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.33%
median of 447 covered companies
CURRENT VS SECTOR MEDIAN
-1143.85%
vs the sector median at left
Elicio Therapeutics, Inc.
Market Cap
$36.23M
Return on Equity (ROE)
-476.77%
TTM Avg
N/A
3Y Avg
-422.57%
5Y Avg
-254.34%
Market Cap
$36.54M
Return on Equity (ROE)
-154.06%
TTM Avg
-1.75%
3Y Avg
68.54%
5Y Avg
60.27%
Market Cap
$36.79M
Return on Equity (ROE)
-161.63%
TTM Avg
-60.21%
3Y Avg
-26.37%
5Y Avg
-20.13%
Market Cap
$35.68M
Return on Equity (ROE)
329.02%
TTM Avg
154.76%
3Y Avg
265.18%
5Y Avg
128.71%
Market Cap
$36.26M
Return on Equity (ROE)
-117.97%
TTM Avg
-59.96%
3Y Avg
-42.92%
5Y Avg
-31.82%
Market Cap
$37.67M
Return on Equity (ROE)
-160.05%
TTM Avg
-184.57%
3Y Avg
-168.71%
5Y Avg
-141.15%
Market Cap
$38.38M
Return on Equity (ROE)
-140.36%
TTM Avg
-216.21%
3Y Avg
-112.57%
5Y Avg
-76.80%
Market Cap
$38.41M
Return on Equity (ROE)
-28.65%
TTM Avg
-189.41%
3Y Avg
-194.44%
5Y Avg
-158.64%
Market Cap
$34.65M
Return on Equity (ROE)
-248.21%
TTM Avg
-991.58%
3Y Avg
-655.25%
5Y Avg
-438.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Elicio Therapeutics, Inc. (ELTX) | $36.23M | -476.77% | N/A | -422.57% | -254.34% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.54M | -154.06% | -1.75% | 68.54% | 60.27% |
| DocGo Inc. (DCGO)vs › | $36.79M | -161.63% | -60.21% | -26.37% | -20.13% |
| Elutia Inc (ELUT)vs › | $35.68M | 329.02% | 154.76% | 265.18% | 128.71% |
| Accuray Incorporated (ARAY)vs › | $36.26M | -117.97% | -59.96% | -42.92% | -31.82% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | -160.05% | -184.57% | -168.71% | -141.15% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.38M | -140.36% | -216.21% | -112.57% | -76.80% |
| Incannex Healthcare Limited (IXHL)vs › | $38.41M | -28.65% | -189.41% | -194.44% | -158.64% |
| HeartBeam, Inc. (BEAT)vs › | $34.65M | -248.21% | -991.58% | -655.25% | -438.62% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.79M | -238.24% | 203.84% | 55.01% | 16.87% |
ROE
-476.8%
ROA
-120.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -476.77% |
| 2025-03-31 | -575.92% |
| 2024-03-31 | -800.68% |
| 2023-12-31 | -309.46% |
| 2023-09-30 | -247.61% |
| 2023-06-30 | -124.96% |
| 2023-03-31 | -73.56% |
| 2022-12-31 | -396.95% |
| 2022-09-30 | -27.58% |
| 2022-03-31 | -47.81% |
| 2021-12-31 | -29.54% |
| 2021-09-30 | -105.16% |
| 2021-06-30 | -90.44% |
